Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bard ends deal with drugs-for-devices firm Angiotech:

This article was originally published in Clinica

Executive Summary

CR Bard and Angiotech Pharmaceuticals have, "by mutual agreement", ended a collaboration to develop a paclitaxel-loaded "vascular wrap". Vancouver, Canada-based Angiotech said the five-year partnership was ended because the device firm did not usually invest in such long-term, expensive programmes. Having been responsible for development of the product, which is designed to treat stenosis in peripheral vascular surgery, Angiotech says it will be able to continue the programme independently with no delays or disruptions. Angiotech's most high-profile drug-device partnership to date is with Boston Scientific, which is hoping to launch its paclitaxel-coated stent in the US next year.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT065398

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel